Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises FSN Capital and Seriline in connection with the add-on acquisition of Areff Systems
Mandate

Vinge advises FSN Capital and Seriline in connection with the add-on acquisition of Areff Systems

May 24, 2022 Employment and Benefits IT, Telecommunications and Outsourcing M&A Intellectual Property

Vinge advises FSN Capital and Seriline in connection with the acquisition of Areff Systems AB from its founders. The founders remain in the merged company and has reinvested a significant proportion of the purchase price in the group.

At the end of February 2022, the private equity firm FSN Capital acquired a majority stake in Seriline with the ambition of consolidating the market for physical and digital identity and access control. The acquisition of Seriline is now followed up with the acquisition of Areff Systems, where FSN Capital accounts for a majority of the financing. Areff Systems works with security and identification solutions and currently has 18 employees. The acquisition of Areff Systems will increase Seriline’s turnover with almost 50 percent to around SEK 150 million for 2022.

Vinge’s team mainly consisted of Johan Winnerblad, Maria Dahlin Kolvik, Eléonore Friberg and Ebba Nyberg (M&A), Mathilda Persson (IT), Sara Strandberg (Employment) and Axel Lennartsson (IPR).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025